FDA Approves Botox Cosmetic (OnabotulinumtoxinA) for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines

DUBLIN, Oct. 3, 2017 /PRNewswire/ -- Today Allergan plc (NYSE: AGN) announced the FDA approval of Botox Cosmetic for its third indication, the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news